Schering-Plough Corporation
Generated Monday November 30, 2009 04:21 AM
hire
departure
internal move
global 
local 
blog Fourteen university-affiliated physicians collected more than $400,000 from the makers of the anti-cholesterol drug Vytorin as part of a campaign to encourage the use of the medication. The 2008 campaign went on after an internal company study showed that the drug, with several billion dollars in sales, had little or no overall value for most patients.
"
Merck's Cholesterol Drugs—Low Hanging Fruit?
Smaller acquisitions are what we expect to see going forward," - Jason Richardson
Report: Large Companies Still Looking for Acquisition Targets
Launching a new product creates a significant growth opportunity, and Qutenza has great potential to deliver substantial value to patients, physicians and NeurogesX. The board and management team have executed an impressive clinical and regulatory strategy for Qutenza on par with biopharmaceutical industry leaders. I look forward to joining the board and advising on the commercial infrastructure and upcoming launch." - John A. Orwin
NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
There are very few responsibilities for which we are jointly responsible. For example, company strategy, brand, people policy and financial outcome, those are undividable. But for business lines, service lines, geography, and functions, we have clear division among ourselves with some balance. Suresh looks at manufacturing, retail, energy and utilities, and I oversee telecom, financial services, media and technology."
Indian firms getting used to the 'power of two'
The joint heads may be, in reality, performing the role of chief operating officers responsible for two strategic business units or geographies,"
India Inc discovers the power of two
Most of the cuts will be layoffs and will be made outside the U.S. Mr. Weldon declined to elaborate further, except to say that potential health reform in the U.S. wasn't a factor because its shape and impact remain uncertain. - Mr. Weldon
J&J Plans Staff Cut Of Up to 8,200 Jobs
The lead investigator, cardiologist Allen Taylor of the Washington Hospital Center, said it wasn't for safety reasons but has declined to elaborate . - Peter Kim
Merck/Schering Cholesterol Drugs At Another Crossroads (DJ)
Merck's Cholesterol Drugs—Low Hanging Fruit? Health Beat Nov 26,'09
If an expensive, name-brand cholesterol drug costs four times more than a generic but provides no clear clinical benefit, why do insurers—both public and private—continue to pay for it? The answer, in the case of Vytorin, a combination of two...
Check Out Hedge Funds' 50 Favorite Stocks Investing to Wealth - Macroaxis Blog Nov 24,'09
Goldman Sachs (GS) is out with a new overview of the hedge fund industry, examining several aspects of what funds are doing. For example, it notes that while hedge funds have generally "re-risked", they also continue to diversify their holdings. You can see here, for example, that the density of the average hedge fund's top 10 holdings has been falling all year.
Ligand Nabs $2M From Merck Xconomy Nov 19,'09
San Diego-based Ligand Pharmaceuticals (NASDAQ: LGND) said today it has received $2 million in milestone payments as part of research collaboration with Merck that is due to expire next month. The partnership started with Organon, which was later acquired by Schering-Plough, which was then acquired by Merck.
Phase Two Capital Observer Nov 19,'09
My thesis in entering my pharmaceutical trade was that pharmaceutical stocks would make a move in two phases. The first phase would come with the closing of the Pfizer/Wyeth and Merck/Schering Plough mergers. I believed that would lead to an initial move higher.
"Make-Whole Call" Rights Expire Tomorrow, November 19th, 5 p.m., E.S.T. Shearlings Got Plowed Nov 18,'09
Yesterday, I answered some questions on another chat-board about the Old Schering-Plough, now " New " Merck 6% Convertible Preferred issue, and how it is affected by the reverse merger. Given that tomorrow is the last day to make this election, I though I'd re-print some of those observations, slightly massaged, here. [ Editor's aside : Almost by dint of capital markets
Following Fred: How Hassan Will Spend His Time Pharmalot Nov 18,'09
Now that Fred Hassan is no longer the chief executive of Schering-Plough - or any other drugmaker - since Merck finally scooped up its rival, Fred has been busy accepting invitations to join the boards of various other corporations. Apparently, his experience selling drugmakers - don't forget his time running Pharmacia - is seen as [...]